UK And Ireland Neuroendo¢rine Tumour Society Limited Charity No. 1148145 Company No. 06672185 Trustees, Report and Unaudited Accounts 31 August 2025 R9gislered Address.. Starling House Unit 1600 B Th"Jffj bi or* Bradley Stoke Bristol BS34 8YU
UK And Ireland Neuroendocrine Tumour Society Limited Contents Pages 2to6 Trustees, Annual Report Independent Examinerfs Report Statement of Financial Activities 8t09 Balance Sheet io Notes to the Account5 Ilto15 Detatled Statement of Financial Activities 16to 17 Page I
The trustees, who afft also directors of the charity for the purposes of the Companies A¢1 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2025. Trustees The Iruslees, who are also the directors for the purposes of eompany law. and who served during the year and up lo the dale of signature of Ihe unaudited finaneial slalemenls were.. ProfT H Shah Prof C Thirfwell - resigned 2 December 2024 Prof M Prilchard Prof R Srirajaskanlhan Dr A Munir- appointed 2 December 2024 None of the directors has any benefscial interest in the company. All of the Iruslegs ale members of the company and guarantee to contribute £1 in the event of winding up. Governing document The UK and Ireland Neuroendocrine Tumour Society Limited IUKI NETS) is consliluled by ils MemorandLJm & Articles of Association. adopted by the membership on 7 December 2015, and is registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charty on 16 July 2012. Organisatlonal structure The Soaety ha5 four main categories of membèrship as follows.. Clinician,. Scientist,. Nurse and Allied Health Professional Members. Each ol these categories is broken down into Career stages. All members are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or scientists interested in promoting the objects. The S¢xiety is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair or Chair-elect, Treasurer and Secrelaryl, supported by a wider Executive Committee. which includes ¢hairs of the sub committees. All Executive Officers and Executive Committee members are elected by member ballot. Risk management The trustees have a duly lo identify and review the r4sks lo which the charity is exposed and to ensure appropriate controls are In place lo prowde reasonable assurance against fraud and error. Page 2
Objectives and activities The chafity's objects are to promote for the public benefit research. education and clinical practice in neuroend¢XTine lumours by the organisalion of conferences. training courses and publications, by raising public awareness. liaison with national and international legislators. and by any other appropriate means. The Society aims lo improve the diagnosis and therapy of patients with n$uroendo¢rine lumour5 within a national multidisciplinary and scientific context. In furtheran of rts objects, the S¢xiety Shall have the foll¢)wing powers.. 1. To arrange and provido for the holding of meetings, lectures and seminars. 2. To procure lo be written and print. publish, issue and circulate graluilou$ly or otheise such papers. periodica15, pamphlets or other documents. 3. To raise ftjnds and lo invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any pemianenl trading activities in raising funds for its primary charitable objed"ves. 4. To Co-operate, associate or affiliate with any other charitable instilulion$. S. To do all such other lawful things as are necessary for the attainment of the above objectives. The summary of main adivities in relation lo the charity objectives are as follows.. Annual Scienliffc Meeting Provision of travel grants Provision of meeting awards Allocation of research grants provided by NeurndoCrine Cancer UK Provision of educational aclivilie5 {webinars and NET for Newcomers training day} Guideline development Publiclheallhcare professional engagement in association wth Neuroendocrine Cancer UK Promotion of Tesearch All trustees have had regard lo the Charity Comrnigsion's guidance on public benefit when planning for the Society's aclivilies. Achievements and perfonnance UKI NETS 22nd Annual Conference: Cardlff The 22n4 Annual Conference of the Society was held al Mercure Holland House Hotel in Cardrff on Monday 2 December 2024. The programme contained sessions focused on.. Mulli-Disciplinary Challenges in Clinical Practice., clinical trials overview,. immunotherapy in patients with high grade NEN5', recent developments in PRRT", MEN Syndromes and Challenge5', a NET Iransl*ional medicine session and a NET nurses. session. Posters and oral Communications were presented The conference ended with a Prize Giving session and a lifetime achievement award was presented during the day. Satellite symposia were also held by sponsors. Page 3
Provlslon of travel grants Five travel grants were awarded lo the presenleTS of the best scoring abslrads for the conference (excluding physicians in post more than 5 yearsl. Four were awarded free membership for a year," one current member was awarded £100. Provision of meeting awards Prizes were awarded lo the top thrge best scoring clinal and scientific posters and the best oral comrnunicalion al the 22Thd Annual Conference. Provision of Research grants Neuroendocrine Caneer UK INCUKI, in asSlatiOn with UKINETS, awarded pump priming grants of £25k each lo provide pumppriming funds lo support research projects designed lo improve outcomes fo¥ patient$ with neuroendocrine cancer. Public Engagement UKI NETS members have been involved with and 5UPPOrting the Neuro&ndocrine Cancer UK awareness campaign for healthcare professionals, 'Spotlighl on Neuroendocrine Cancer,. developing NET overviews for those who see NET patients bul are not experts. Educational actlvltles NETS for New¢omers'. On 9th May 2025 UKINETS presented the eighth annual one doy coutse for d¢Xtors and HCPS of all 5peeiallies who wished to learn more about Neuroendocrine Tumours. It was held face to face in Manchester. The course was delivered by an expert multidisciplinary fa¢ully and Included a 'mock MDT. practice in small groups. Approximately 34 HCPS attendèd and feedback was very positive. 6 CPD points were awarded lo attendees. Webinars.. UKINETS continued lo deliver ils series of educational webinars, led by the Education and Training Committee. Webinars were delivered on NET oncology and theragnostics The webinars are free to attend for both members and non-members of UKINETS. Guideline development The UKINETS Clinical Practice Committee continues lo create clinical guideline documents for its Bilesi2e Guidance library, available on the UKINETS website. As well as the Creation of new guidan, existing guidance was reviewed and updated. Dietltlans, Worklng Group The AHPIDielilian representative on the Executive Committee also chairs the UKINETS Dietitians, Working Group. The group delivered a teaching session for dielilians and nurses, compiled daia from UK Centre of Excellence NET centres on dielilian support lor lack ofj for the NET MDT and began planning a NET nutrition study day for early 2026. Sponsor Support There was financial support lo the Society in the form of sponsorship from phamiaceutical and technology companies with products relevant lo NETS. The majorrty of the funding was provided as sponsorship for the National Conf9ren and NETS for Newcomers frainin9 Day. Page 4
Website The charity's website promdes an important tool lo infom members and the general public about the artivilies of the Society. as well as upd*e$ in NET research. htt ."Ilww.ukine Communications UKI NETS cornmunicales with ils members by means of an e-newsletter delivering news from the Society and the wider field. In addition, the charity highlights on its website news and research relating lo the field of neuroendocrine lumours. The charity also has Its own X aceounl @UKINETS. The Society is in the process of investigating the use of other social neOrkS. Cllnlcal Trlals and Research Development UKINETS include5 a summary of recent clinical trials related to NETS on ils websf(e and at it$ annual scientific conference. UKINETS has continued lo manage a pw011 lo sel up a national database for NETS lo faciliiale valuable future research. Link wrth the European Neuroendocrine Tumour Soclety IENETS) UKI NETS Continues to provide optional inclusive membership lo fts members lo its European partner Society, ENETS. Through membership of ENETS. UKI NETS members have access lo Journal of Neuroendocrinology and a reduced rate for the ENETS annual conference. A member of UKINETS sils on the Executive Committee of ENETS. Financial review Princlpal fundlng sources Income lo the Society 1$ mainly generated through industry support, the annual ¢onference and membership subscriptions. Personal donalionsllegacies are receNed on an ad hoc basis. Reserves policy The reserve policy takes into consideration the major risks that Could fa the Society. It 15 the policy of the Society lo maintain unrestricted funds. which are the free reserves of the charity. The reserves are held al a level that ensures the financial viability of the Society. That level is currently deemed lo be one that equates lo a minimum of two years, expenditure. The officers of the Society will be Teviewing this policy lo ensure it still fil for purpose The balance sheet indicates that there are £168,917 unreslricled funds as at 31 August 2025. This provides suffi¢ienl funds lo cover management, administration and support costs. Page 5
Plans for futuro porlods The UKI NETS 23rt Annual Conferen¢9 Is scheduled to bè hald in London in December 2025, with abstracts submitted and posters and oral ¢ornmunications presented as usual. Olher plans for the coming year include.. Holding a NET Nutrition Study Day in January 2026 Awarding 3 x Pump Primin9 Grarrts and 2 x Practice Changing grants on behalf ot NCUK tn February 2026 Holding a further NET8 for Ngw¢orners tralning event in Sheffield in June 2028 Further developing the library of bit8 size ¢linical guidance for the websita Continuing the d81ivéry of a prcAJramme of free educational webinars on varied topics relating to NETS- to improve education and awareness for HCPS, possibly collaborating with partners to deliver more Continuing to plan and deliver a national NET databas& for rosgafch purposes Collaborating ¥th NCUK to manage the Neuroondo¢rfn¢ Cancer Priority Setting Partnership with the James Lind Alliance Endorsement of'Br<)nchopulmonary Carcinoids Ltnveiled, la workshop delivered by t Chrisliel in January 2026 Provi¢Jing feedback on external clinical guidelines where approprtat8 Continuing to secure funding Irorn ¢orporale donors Continuing lo develop communications with members The Trustgcs Report was approved by the Board of Trustees and signed on Ils behasf by.. Prof R Srirai83kanth8n Tru$lge Dated.. 2?/z/L I CCK) @n P(th(w JGY F33* 8Y Page 6
UK And Ireland Neuroendoerine Tumour Society Llmited Indepertdent Examiners Report Independent Examiner's Report to the trustees of UK And Ireland Neuroendocrine Tumour Society Limited I report to the charity trustee5 on my examination of the financial statements of UK And Ireland Neuroendocrine Tumour Society Limited for the year ended 31 August 2025. Re5pon5ibilities and basis of report As the charity's trustees of the company land a150 Its directors for the purposes of company lawl you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 21X>61'the 2006 Act. Having satisfied myself that the financial statements of the Charlty a not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's ftnancial statements as carried out under seetion 145 of the Charities Act 20111.the 2011 Act'l. In earrying out my examination I have followed the Directions given by the Charity Commission under section 145151 Ibl of the 2011 Act. Independent examiner'5 Statement I have completed my examination. I can confirm that no material matters have come to my attention in connection with the examTrnation giving me cause to believe.. accounting records were not kept in accordance with section 386 of the 2006 Act.. or the financial statements do not accord with those records,. or the financial statements do not comply with the accounting requirements under section 396 of the 2006 Act other than any requirement that the financial statements give a 'true and fair. view which is not matter considered as part of an independent examination,. or the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021. I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached. Andy Hopkins BVSC Latham House 33-34 Paradise Street Birmingham BI 2AJ 19 lanLtary 2026 Page 7
UK Artd Ireland Neuroendocrine Tumour Society Umlted Statement of Financial Activities for the year ended 31 August 2025 Unrestricted funds Restricted funds Total funds Total funds 2025 2025 2024 2025 Notes 5ncome and endowments from: Donations and legacies Charitable activities Other 23,526 104.234 2CK) 23,526 104,234 2CK) 23.252 114,228 Totsl 127,960 127,960 137,480 Expenditure on., Charitable activlties 56,149 60,285 5,068 61,217 60,285 70,435 51.486 Other Total 116,434 5,068 121,502 121,921 Net gains on investments Net income 11,526 15,0681 13961 6.458 IS,559 Transfers between funds 396 Net income before other %ains/llossesl 11,922 15.4641 6,458 15,559 Other gains and losses Net movement in funds 11,922 15,4641 6.458 15,559 Reconciliation of funds: Total funds brought foNard 156.995 5,464 162,459 146,900 Total funds carrled forward 168.917 168,917 162,459 Page 8
UK And Ireland Neuroendocrine Tumour Society Llmited Summary lrt¢ome and Expenditure Account lor the year ended 31 August 2025 2025 2024 Income 127,960 137,480 GTOSS income for the year Expenditure 127,960 137.480 121,502 121,922 Total expendlture for the year Net income before tax for the year 121,502 121,922 6,458 15,558 Net income for the year 6,458 15,558 Page 9
UK And Ireland Neuroendocrine Tumour So¢léty Limited Balance Sheet at 31 August 2025 Company No. 06672185 Ilotes 2025 2024 Current assets Debtors sh at bank and in hand li 30,447 144,492 174,939 16,0221 168.917 31,254 137,060 168,314 15,85SI 162,459 Creditor5: Arnount falling due within one year Net rrent assets 12 Total assets less current Ilabllitles 168,917 162,459 Net assets eMcludinK penslon asset or Ilablllty 168.917 162,459 Total net assets 168,917 162,459 The funds of the charlty Restrirted funds Restricted income funds 13 5,464 5,464 Unrtstrlcted funds General f¢Jnd5 13 168,917 156,995 168,917 156,995 Reser¥•s Totsl funds 168,917 162.459 These account5 have been prepared in accordance with the special provisions of Part IS of the Companies Act 21JJ6 relating to small cornpanies. For the year ended 31 Au8USt 2025 the company was entitled to exemption undèr section 477 of the Companies Art 21J06 relatin8 to small companies. The rnembers have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting record5 and the preparation of accounts. Approved by the board on And si8ned on its behalf by.. R. Srirajaskanthan Trustee Date.. Pagc 10
UK And Ireland Neuroendocrine Tumour Society Limited Notes to the Account5 for the year ended 31 August 2025 l Accounting policies Basis of preparation The financtal statements have been prepared in accordance with Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 (effective I january 20151 Icharities SORP IFRS 10211, the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 and the Companies Act 2006. Change in bas15 of a¢¢ounting or to previou5 a¢counts There has been no change to the accounting policies Ivaluation rules and method of accounting) since last year and no changes have been made to accounts for previous years. Fund accounting Unrestricted funds These are available for use at the discretion of the trustees in furtherance of the general objects of the charity. These are unrestricted funds earmarked by the trustee5 for particular purposes. These are unrestricted funds which include a revaluation reserve representing the restatement of investment assets at their market values. These are available for use subject to restrirtions imposed by the donor or through term5 of an appeal. Designated funds Revaluation funds Restricted funds Income Recognition of income Income is included in the Statement of Financial Actlvities ISOFAI when the tharity becomes entitled to, and virtually certain to receive. the income and the amount of the income can be measuTed with sufficient reliability. Income with related Where income has related expenditure the Income and related expendituie is expenditure reported gross in the SOFA. Donations and legacies Voluntary income received by way of grants, donations and gifts is included in the the SOFA when receivable and only when the Charity has untonditional entitlement to the income. Tax reclaims on Income from tax reclaims is included in the SOFA at the same time as the donations and gifts gift/donation to which it relates. Donated services These are only included in income (with an equivalent amount in expenditure) and facilities where the benefit to the Charity is reasonably quantlfiable, measurable and material. Volunteer help The value of any volunteer help received is not included in the accounts. Investment income This is included in the accounts when receivable. Gainslllossesl on Thi5 includes any gain or1055 re5ultin8 from revaluing investments to market value revalLtation of fixed at the end of the year. assets Gains/llosse51 on investment assets This includes any gain or1055 ori the sale of investments. Pagell
UK And Ireland Neuroendocrine Tumour Society Limited Notes to the A¢¢ounts Expenditure Recognition of expenditure Expenditure is recognised on an accruals basis. Expenditure include5 any VAT which tannot be fully recovered, and is reported as part of the expenditure to which it relates. Expenditure on These comprise the costs associated with attracting voluntary income, fundraising raising funds trading cost5 and investment management costs. Expenditure on These comprise the costs incurred by the Charity in the del¢very of it5 activities and charitable activities services in the furtherance of its objects, including the makin8 of grants and governance costs. All grant expenditure is accounted for on an actual paid basis plus an accrual for grants that have been approved by the trustees at the end of the year but not yet paid. These include those costs associated with meeting the constitutional and statutory requirements of the Charity, including any audit/independent examination fees, cost5 linked to the strategic management of the Charity, together with a share of other administration costs. These are support costs not allocated to a particular activity. Grants payable Governance costs Other expenditure Taxation The charity is exempt from corporation tax on its charitable activities. Trade and other debtors Trade and other debtors are fecognised at the settlement amount due after any trade distount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. 2 Company status The company is a private company limited by guarantee and consequently does not have share capital. Page 12
UK And Ireland Neuroendocrine Tumour Society Limited Notes to the Accounts 3 Statement of Financlal A¢tivlties- prior year Unrestricted fund5 Restricted funds Total funds 2024 2024 2024 Income and endowments from: Donations and legacies Charitable aclivities 23,252 114,228 23,252 114,228 Total 137,480 137,480 Expenditure on: Charitable activities 121,922 121,922 Total 121.922 121,922 Net income 15,558 15,558 Net income before other gainslllossesl Other gains and losses.. Net movement in funds 15,558 15,558 15,558 15,558 Reconciliation of funds: Total funds brought fornard Total funds ¢arried forward 141,436 5.464 146,900 156,994 5,464 162.458 4 Income from donations and le8acie5 Unrestrlrted Total Total 2024 2025 Donations and gifts Membership Fees 2,064 21.462 2,064 21,462 23,526 4,350 18,902 23,252 23,526 5 Income from charltable activities Unrestrirted Total Total 2025 2024 Sponsorship 104,234 104,234 104.234 104,234 114,228 114,228 6 Other income Unrestricted Total 2025 Total 2024 200 2(X) 200 200 Page 13
UK And Ireland Neuroendocrine Tumour Society Llmited Notes to the Account5 7 Expenditure on Charitable activities UnrestrS¢ted Restricted Total Total 2024 2025 Expenditure on choritoble activities Conferences and newsletters Application development tosts 56,149 56,149 70.308 5,068 5,068 Governance costs 127 56,149 5,068 61,217 70,435 8 Other expenditure Unrestricted Total 2025 Total 2024 Other operating costs Management and Accountancy 44,623 44,623 37,238 15,662 15,662 14,248 60,285 60.285 51,486 9 Net income before transfers 2025 2024 This is stated after charging- Independent Examinerfs fee io stsff costs No employee received emoluments in excess of £60,000. 11 Debtors 1,440 1,440 2025 2024 Other debtors Prepayments and accrued income 5,447 25,000 30.447 31,254 31,254 12 Creditors: amounts falling due within one year 2025 2024 Accruals 6.022 6,022 5,855 5,855 Page 14
UK And Ireland Neuroendocrine Tumour Soclety Llmlted Notes to the Account5 13 Movement in funds Incoming resources At31 Resour¢es expended Gross transfers Atl (including September other 2024 galns/losses1 Au8USt 2025 Restricted funds: Restricted income fund5'. TransNet 5,464 15,0681 13961 TotGI 5,464 15,0681 13961 Unrestricted funds.. General funds 156,995 127,960 1116.4341 396 168,917 Total funds 162.459 127,960 1121.5021 168,917 Purpose5 and restrictions in relation to the funds.. Restricted funds.. TransNet 14 Analysis of net assets between funds Unrestricted funds Restricted fvnds Total Net current assets 163,470 163.470 5,447 5,447 168,917 168,917 15 Reconclllatlon of net debt Atl At31 September 2024 August 2025 Cash flows Cash and cash equivalents 137,060 137,060 7,432 7,432 144,492 144.492 Net debt 137,060 7,432 144.492 16 Related party disclosure5 Controlling party The company 15 limited by guarantee and has no share capf(al- thus no single party controls the compdny. Page 15
UK And Ireland Neuroendocrine Tumour Soclety Limited Oetailed Statement of Flnanclal Artlvities for the year ended 31 Au8USt 2025 Unrestricte Restrlcted funds d fund5 2025 Total funds 2025 Total funds 2024 2025 Income and endowments from: Donations and legacies Donatlons and glfts Membership Fees 2,064 21,462 23,526 2,064 21,462 23,526 4,350 18,902 23,252 Charitable activities Sponsorship 104,234 104,234 104,234 104,234 114,228 114.228 Other 2¢J) 200 200 200 Total income and endowments 127,960 127,960 137,480 Expenditure on: Charitable activities Conferences and newsletters Application development costs 56,149 56,149 5,068 61.217 70,308 5,068 5,068 56.149 70,308 Governance costs 127 127 Total of expenditure on Charitable artivities 56,149 5.068 61,217 70,435 General admlnistratlve costs, including depreciation and amortisation Software, IT support and related costs 3.136 3,136 5,095 Subscriptions Sundry expenses 9,770 31,717 44,623 9,770 31,717 44.623 5,643 26,500 37,238 Legal and professional costs Auditllndependent examination fees Management charges 1,440 1,440 1,160 14,222 15,662 14,222 15.662 13,088 14,248 Total of empenditure of other Costs Total expenditure Net gains on investments 60,285 60.285 51,486 116,434 5,068 121.502 121,921 Page 16
UK And Ireland Neuroendocrine Tumour Soclety Llmlted Detailed Statement of Financial Activltles Net income 11,526 15,0681 6,458 15,559 Transfers between funds 396 13961 Net income before other gainslllossesl Other Gains 15,559 11,922 15,4641 6,458 Net movement in funds 11,922 15,4641 6,458 15,559 Reconciliation of fvnds: Total funds brou8ht fotward 156.995 5,464 162.459 146,900 Total funds carried forward 168.917 168,917 162,459 Page 17